In December, Vanda Pharmaceuticals gained FDA approval for its motion sickness drug Nereus. But a much larger patient population may be in store for the oral therapy as the Washington, D.C.-based ...

In connection with the deal, Assertio has divested the rest of its assets to New Jersey generics and branded drugmaker ...

AbbVie is spearheading a new battle in pharma's long-running fight to reform the federal government’s 340B drug discount ...

Robert F. Kennedy Jr. is starting a podcast. Unveiling the show on social media, the Department of Health and Human Services ...

Biogen has forged a settlement with investors who claimed the company misled them in describing how it gained a controversial ...

After more than a decade in charge of the most influential organization representing the U.S. pharmaceutical industry, the ...

With another year of double-digit revenue growth in the books, Amgen’s longtime helmsman Robert Bradway continues to sit ...

Pfizer is making more changes to its layout in California by stepping away from a South San Francisco office site that used ...

Japan’s Shionogi is joining the spate of drugmakers to announce manufacturing commitments in the U.S. since last year, albeit ...

Cognito Therapeutics is partnering with a nonprofit to “Change the D-Word,” aiming to eliminate the use of “dementia,” a ...

U.S. Olympic gold medal-winning athlete Lindsey Vonn is once again teaming up with infectious disease biopharma Invivyd for a ...

Johnson & Johnson’s immunology drug Tremfya is looking to challenge AbbVie’s dominance in 2026, securing the top spot as the ...